- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04084678
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (CAPACITY)
October 19, 2023 updated by: United Therapeutics
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
ROR-PH-302 is a 28-week multicenter, randomized, double-blind, placebo-controlled study.
Subjects who meet entry criteria will be randomly allocated 2:1 to receive ralinepag or placebo, in addition to their PAH-specific background therapy, as applicable.
The primary endpoint is change from Baseline in peak VO2 (assessed by CPET) at Week 28.
All subjects who complete the study on study drug through Week 28 will have the option to receive ralinepag in an open-label extension (OLE) study.
Subjects who discontinue study drug prior to Week 28, as well as those who complete Week 28 on study drug but choose not to participate in the OLE study, will be contacted every 6 months and at the end of the study to determine their survival status.
Subjects who prematurely discontinue study drug or withdraw from the study for any reason will not be eligible to enter the OLE study.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ciudad Autónoma de Bs. As., Argentina, 1280
- Hospital Britanico de Buenos Aires
-
Corrientes, Argentina, W3400AMZ
- Instituto de Cardiologia de Corrientes
-
-
-
-
New South Wales
-
North Ryde, New South Wales, Australia, 2109
- Macquarie University
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital, Dept Respiratory and Sleep Medicine
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- The Prince Charles Hospital
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
-
-
-
Linz, Austria, 4020
- Ordensklinikum Linz GmbH, Elisabethinen
-
Vienna, Austria, 1090
- AKH Wien, Innere Med. II, Kardiologie
-
-
-
-
-
Brussels, Belgium, 1070
- Erasme University Hospital - Department of Cardiology
-
Leuven, Belgium, 3000
- Gasthuisberg University Hospital - Department of Pulmonology
-
-
-
-
-
Porto Alegre, Brazil, 90035074
- Centro de Hipertensão Pulmonar
-
-
MG
-
Belo Horizonte, MG, Brazil, 30441-070
- Hospital Madre Teresa
-
-
SP
-
São Paulo, SP, Brazil, 04037-002
- Hospital Sao Paulo
-
São Paulo, SP, Brazil, 05403-000
- Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo - InCor-HCFMUSP
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T1Y 6J4
- Peter Lougheed Center
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- London Health Science Centre- Victoria Hospital
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Germany, 69126
- Thoraxklinik-Heidelberg, Zentrum für Pulmonale Hypertonie
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- Universitätsklinikum Carl Gustav Carus TU Dresden, Medizinische Klinik I, Abteilung für Pneumologie
-
-
-
-
-
Milano, Italy, 20122
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
-
Milano, Italy, 20138
- Centro Cardiologico Monzino, IRCCS
-
Rome, Italy, 00161
- AOU Policlinico Umberto I
-
-
-
-
-
Białystok, Poland, 15-276
- Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego
-
Otwock, Poland, 05-400
- Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Oddział Kardiologiczny
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spain, 08036
- Hospital Clinic i Provincial de Barcelona
-
Madrid, Spain, 28041
- Hospital Universitario 12 de octubre
-
-
-
-
-
London, United Kingdom, W12 0HS
- Imperial College Healthcare NHS Trust
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Banner University Medical Center (University of Arizona)
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
Florida
-
Tampa, Florida, United States, 33606
- Tampa General Hospital/University of South Florida Center for Advanced Lung Disease and Lung Transplant
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin/Froedtert Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent form.
- At least 18 years of age.
- Primary diagnosis of PAH.
- Has had a diagnostic RHC performed at or within 3 years before Screening (or at Screening if one is not available) that is consistent with the diagnosis of PAH.
- Has World Health Organization (WHO)/New York Heart Association (NYHA) Functional Class (FC) II to III symptoms
- Must be on a stable dose of PAH-specific oral therapy, defined as no change in dose or regimen for at least 90 days prior to randomization. Allowable PAH-specific therapy is an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor (PDE5-I) or a soluble guanylate cyclase (sGC) stimulator. Subjects may be on a stable dose of either a PDE5-I or a sGC stimulator, not both.
- Has a 6-minute walk distance (6MWD) of ≥150 meters at Screening.
- Has a peak VO2 of ≥9 to <18 mL/min/kg during the Screening CPET, as assessed by the CPET core laboratory.
- If the subject is taking concomitant medications that may affect the clinical manifestations of PAH, the subject must be on a stable dose for at least 30 days prior to randomization. The exception is that the dose of diuretics must be stable for at least the 10 days prior to randomization.
- Both male and female subjects agree to use a highly effective method of birth control throughout the entire study period from informed consent through to the Week 28 Visit/28-day Follow-up Visit, if the possibility of conception exists. Eligible male and female subjects must also agree not to participate in a conception process during the study and for 30 days after the final dose of study drug. Eligible male subjects must agree not to participate in sperm donation for 90 days after the final dose of study drug. Women who are surgically sterile or postmenopausal are not considered to be of childbearing potential. If of childbearing potential, female partners of male study participants should agree to utilize medically acceptable methods of contraception for the duration of study participation.
Exclusion Criteria:
- For subjects with known human immunodeficiency virus-associated PAH, a cluster of differentiation 4 T-cell count <200/mm3 at Screening.
- Has 3 or more left ventricular disease/dysfunction risk factors.
- Symptomatic coronary artery disease and/or myocardial infarction within past 6 months.
- Current symptomatic aortic or mitral valve disease.
- Has evidence of more than mild lung disease on pulmonary function tests performed within 1 year prior to, or during, Screening.
- Has evidence of thromboembolic disease as determined by ventilation-perfusion lung scan or local standard of care diagnostic evaluation at or after diagnosis of PAH.
- Current diagnosis of ongoing and clinically significant sleep apnea as defined by the Investigator.
- Requires use of supplemental oxygen during CPET.
- Respiratory exchange ratio <1.0 at Screening CPET as determined by the CPET core laboratory.
- Acute non-cardiac disorder that may affect exercise performance or be aggravated by exercise (eg, infection, renal failure, thyrotoxicosis).
- Male subjects with a QTcF >450 msec and female subjects with a QTcF >470 msec on electrocardiogram (ECG) recorded at Screening and analyzed by the central ECG laboratory. Subjects with evidence of intraventricular conduction delay, defined as a QRS interval >110 msec, will be excluded if QTcF is >500 msec for both males and females.
- Severe chronic liver disease (ie, Child-Pugh Class C), portal hypertension, cirrhosis, or complications of cirrhosis/portal hypertension (eg, history of variceal hemorrhage, encephalopathy).
- Confirmed active infection with hepatitis B virus or hepatitis C virus.
- Subjects with alanine aminotransferase or aspartate aminotransferase ≥3 times the upper limit of normal or total bilirubin ≥2 times the upper limit of normal at Screening.
- Chronic renal insufficiency as defined by an estimated glomerular filtration rate using the Modification of Diet in Renal Disease Study equation of <30 mL/min/1.73 m2 or requiring dialysis at Screening.
- Hemoglobin concentration <9 g/dL at Screening.
- Subjects treated with an intravenous, subcutaneous, inhaled, or oral prostacyclin pathway agent (eg, epoprostenol, treprostinil, iloprost, beraprost, or selexipag) for PAH within 90 days of randomization (use in vasoreactive testing is permitted). Subject is not eligible if previous prostacyclin therapy was stopped for a safety or tolerability issue related to systemic prostacyclin adverse effects.
- Subject has pulmonary veno-occlusive disease.
- Malignancy diagnosed and/or treated within 3 years of Screening, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.
- Subject tests positive for amphetamine, cocaine, methamphetamine, methylenedioxymethamphetamine, or phencyclidine in urine drug screen performed at Screening, or has a recent history (6 months) of alcohol or drug abuse. Subjects will not be excluded due to a positive drug screen caused by prescribed medications.
- Initiation or discontinuation of a cardio-pulmonary rehabilitation program based upon exercise within 90 days prior to Screening and/or planned during study participation.
- Prior participation in any study of ralinepag or another interventional clinical study with medicinal products within 30 days prior to Screening. Concurrent participation in registry or observational studies is allowed, if the subject can fulfill all other entry criteria and comply with all study procedures.
- Any reason that, in the opinion of the Investigator, precludes the subject from participating in the study (eg, any previous or intercurrent medical condition) that may increase the risk associated with study participation or that would confound study analysis (eg, right-to-left shunt detected during CPET) or impair study participation or cooperation.
- Known hypersensitivity to ralinepag or any of the excipients.
- Life expectancy <12 months based on the Investigator's opinion.
- Women who are pregnant, lactating, or breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ralinepag
Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the individual maximum tolerated dose (maximum dose of 1400 mcg)
|
Oral ralinepag
Other Names:
|
Placebo Comparator: Placebo
Matching placebo tablets (oral)
|
Matching oral tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in peak VO2 assessed by CPET
Time Frame: Baseline to Week 28
|
Peak VO2 by CPET was measured at Baseline (prior to starting study drug) and Week 28
|
Baseline to Week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)
Time Frame: Baseline to Week 28
|
NT-proBNP was measured at Baseline (prior to starting study drug) and Weeks 4, 8, 12, 16, 20, 24 and 28
|
Baseline to Week 28
|
Change from Baseline in Minute Ventilation (VE)/Carbon Dioxide output (VCO2) slope
Time Frame: Baseline to Week 28
|
VE/VCO2 slope (from CPET) was calculated at Baseline (prior to starting study drug) and Week 28
|
Baseline to Week 28
|
Change from Baseline in health-related quality of life measured by the Short Form Health Survey (SF-36) Scores
Time Frame: Baseline to Week 28
|
SF-36 was assessed at Baseline (prior to starting study drug) and Weeks 16 and 28.
The SF-36 consisted of 36 questions in 8 health categories (Vitality, Physical Functioning, Bodily Pain, General Health Perception, Role Physical, Role Emotional, Social Functioning, and Mental Health).
Responses to the questions were graded on a numerical scale, with 1 as the best score and higher numbers as worse scores.
The raw scores from the subscales were converted and summed by the Investigator to a total score between 0 and 100 to measure functional health and well-being from the patient's point of view.
The final score range was 0 (representing the lowest possible score; worst health state) to 100 (representing the highest possible score; best health state).
|
Baseline to Week 28
|
Time to First All-cause Non-elective Hospitalization
Time Frame: Baseline to Week 28
|
The time to first all-cause nonelective hospitalization during the study period will be assessed.
|
Baseline to Week 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2021
Primary Completion (Actual)
April 12, 2023
Study Completion (Actual)
April 12, 2023
Study Registration Dates
First Submitted
September 6, 2019
First Submitted That Met QC Criteria
September 6, 2019
First Posted (Actual)
September 10, 2019
Study Record Updates
Last Update Posted (Actual)
October 24, 2023
Last Update Submitted That Met QC Criteria
October 19, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROR-PH-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Ralinepag
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Australia, Bulgaria, Czechia, Hungary, Poland, Romania, Serbia, Slovakia, Spain
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Australia, Hungary, Bulgaria, Czechia, Poland, Romania, Serbia, Spain
-
Everstar Medicines (Shanghai) LimitedCompletedHealthy Volunteer | Pharmacokinetic StudyChina
-
United TherapeuticsEnrolling by invitationCardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract DiseaseUnited States, Spain, Australia, Taiwan, Canada, Singapore, United Kingdom, Italy, Germany, China, Mexico, Argentina, Korea, Republic of, Austria, Greece, Sweden, Portugal, Belgium, Brazil, Bulgaria, Chile, Croatia, Czechia, Denmark, Fr... and more
-
United TherapeuticsRecruitingCardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract DiseaseUnited States, Australia, Austria, Italy, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Argentina, Germany, France, Belgium, Mexico, Brazil, Hungary, Bulgaria, Chile, Czechia, Denmark, Greece, Israel, Netherlands, Pola... and more